EE509 Healthcare Resource Utilization (HCRU) and Associated Costs in Patients With Advanced Merkel Cell Carcinoma (aMCC) in Germany: Analysis From the MCC TRIM Registry Study
Hamid Mahmoudpour, Dina Oksen(Merck KGaA, Darmstadt (Germany)), Dirk Schadendorf(National Center for Tumor Diseases), Emmanuelle Boutmy(Merck KGaA, Darmstadt (Germany)), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Stephan Grabbe(Goethe University Frankfurt), Fabian Ziller(Vivantes Klinikum), Selma Ugurel(Klinikum Bielefeld), Margarita Shlaen, Lisa Zimmer(The University of Sydney), Jürgen C. Becker(Düsseldorf University Hospital), Ulrike Leiter(University of Tübingen), Mairead Kearney(Merck KGaA, Darmstadt (Germany)), C. Gerbhardt(Universität Hamburg), Friedegund Meier, Rudolf Herbst(Helios Klinikum Erfurt), Sebastian Hoff(Merck KGaA, Darmstadt (Germany)), Claudia Pföhler(Saarland University)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k